592 Appendices 711. Goldner WS, Angell TE, McAdoo SL, Babiarz J, Sadow PM, Nabhan FA, et al. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules. Thyroid. 2019;29:1594-1605. https://doi.org/10.1089/thy.2019.0278. 712. Hu MI, Waguespack SG, Dosiou C, Ladenson PW, Livhits MJ, Wirth LJ, et al. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. The Journal of clinical endocrinology and metabolism. 2021;106:2198-2207. https://doi.org/10.1210/clinem/dgab304. 713. Alohali S, Payne AE, Pusztaszeri M, Rajab M, Forest VI, Hier MP, et al. Effect of Having Concurrent Mutations on the Degree of Aggressiveness in Patients with Thyroid Cancer Positive for TERT Promoter Mutations. Cancers (Basel). 2023;15. https://doi.org/10.3390/cancers15020413. 714. Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clinical cancer research. 2018;24:3059-3068. https://doi.org/10.1158/1078-0432. CCR-18-0373. 715. Hernandez-Prera JC, Valderrabano P, Creed JH, de la Iglesia JV, Slebos RJC, Centeno BA, et al. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021;31:36-49. https://doi.org/10.1089/ thy.2019.0650. 716. Murugan AK, Dong J, Xie J, Xing M. Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocrine pathology. 2011;22:97-102. https://doi.org/10.1007/s12022-011-9155-x. 717. Ferru A, Fromont G, Gibelin H, Guilhot J, Savagner F, Tourani JM, et al. The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression. British journal of cancer. 2006;95:1670-1677. https://doi. org/10.1038/sj.bjc.6603479. 718. de Koster EJ, Husson O, van Dam E, Mijnhout GS, Netea-Maier RT, Oyen WJG, et al. Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules. Endocr Connect. 2022;11:e220014. https://doi. org/10.1530/EC-22-0014. 719. Fazeli SR, Zehr B, Amraei R, Toraldo G, Guan H, Kindelberger D, et al. ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule. Thyroid. 2020;30:1528-1534. https://doi. org/10.1089/thy.2019.0191. 720. Figge JJ, Gooding WE, Steward DL, Yip L, Sippel RS, Yang SP, et al. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology? Thyroid. 2021. https://doi.org/10.1089/thy.2021.0119. 721. Zhu Y, Li Y, Jung CK, Song DE, Hang JF, Liu Z, et al. Histopathologic Assessment of Capsular Invasion in Follicular Thyroid Neoplasms-an Observer Variation Study. Endocrine pathology. 2020;31:132-140. https://doi.org/10.1007/ s12022-020-09620-7. 722. Craig S, Khalil M, Eszlinger M, Itani D, Koebel M, Koro K, et al. Malignancy is in the eye of the beholder: Pathologic diagnosis of challenging follicular neoplasms in the era of noninvasive follicular thyroid neoplasms with papillarylike nuclear features and immunohistochemical and molecular adjuncts. Surgery. 2021;169:22-26. https://doi. org/10.1016/j.surg.2020.04.004. 723. Valderrabano P, Khazai L, Leon ME, Thompson ZJ, Ma Z, Chung CH, et al. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocrine-related cancer. 2017;24:127-136. https://doi.org/10.1530/erc-16-0512. 724. Rivas AM, Nassar A, Zhang J, Casler JD, Chindris AM, Smallridge R, et al. ThyroSeq((R))V2.0 Molecular Testing: A Cost-Effective Approach for the Evaluation of Indeterminate Thyroid Nodules. Endocrine practice. 2018;24:780-788. https://doi.org/10.4158/EP-2018-0212. 725. de Koster EJ, Morreau H, Bleumink GS, van Engen-van Grunsven ACH, de Geus-Oei LF, Links TP, et al. Molecular Diagnostics and [(18)F]FDG-PET/CT in Indeterminate Thyroid Nodules: Complementing Techniques or Waste of Valuable Resources? Thyroid. 2024;34:41-53. https://doi.org/10.1089/thy.2023.0337. 726. Thuillier P, Ansquer C, Borson-Chazot F, Lussey-Lepoutre C. Response to De Koster and al. Thuillier P, Benisvy D, Ansquer C, Corvilain B, Mirallie E, Taieb D, et al.: What is the role of functional imaging and isotopic treatment? Ann Endocrinol (Paris) 2022. https://doi.org/10.1016/j.ando.2022.10.008. Ann Endocrinol (Paris). 2023;84:327-328. https://doi.org/10.1016/j.ando.2023.01.002. 727. Kreissl MC, Ovcaricek PP, Campenni A, Vrachimis A, Tuncel M, Giovanella L. The European Association of Nuclear Medicine (EANM)’s Response to the 2023 European Thyroid Association (ETA) clinical practice guidelines for thyroid nodule management and nuclear medicine: a deliberate oversight? Eur J Nucl Med Mol Imaging. 2024. https://doi. org/10.1007/s00259-023-06571-z. 728. Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. Nature. 2018;561:45-56. https:// doi.org/10.1038/s41586-018-0457-8. 729. Central Bureau for Statistics. Ouderen. 2023. https://www.cbs.nl/nl-nl/visualisaties/dashboard-bevolking/leeftijd/ ouderen. Accessed 20 November 2023. 730. National Health Care Institute (Zorginstituut Nederland). Verdiepende analyses zorglasten Zvw 2016-2020. 2021. https://zorginstituutnederland.nl/financiering/publicaties/rapport/2021/12/07/verdiepende-analyses-zorglastenzvw-2016-2020. Accessed 20 November 2023.
RkJQdWJsaXNoZXIy MTk4NDMw